Boothbay Fund Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-9,701
| Closed | -$305K | – | 2146 |
|
|
2026
Q2 | $305K | Buy |
+9,701
| New | +$286K | ﹤0.01% | 1728 |
|
|
2026
Q1 | – | Sell |
-8,733
| Closed | -$204K | – | 2133 |
|
|
2025
Q4 | $204K | Sell |
8,733
-11,683
| -57% | -$260K | ﹤0.01% | 1654 |
|
|
2025
Q3 | $402K | Sell |
20,416
-20,175
| -50% | -$415K | 0.01% | 1290 |
|
|
2025
Q2 | $881K | Sell |
40,591
-14,292
| -26% | -$337K | 0.02% | 725 |
|
|
2025
Q1 | $1.33M | Sell |
54,883
-21,982
| -29% | -$495K | 0.04% | 537 |
|
|
2024
Q4 | $1.6M | Sell |
76,865
-29,362
| -28% | -$631K | 0.04% | 497 |
|
|
2024
Q3 | $2.11M | Sell |
106,227
-14,623
| -12% | -$271K | 0.05% | 499 |
|
|
2024
Q2 | $1.87M | Hold |
120,850
| – | – | 0.04% | 521 |
|
|
2024
Q1 | $1.93M | Buy |
120,850
+12,524
| +12% | +$189K | 0.04% | 522 |
|
|
2023
Q4 | $1.82M | Hold |
108,326
| – | – | 0.05% | 527 |
|
|
2023
Q3 | $1.27M | Buy |
+108,326
| New | +$1.45M | 0.03% | 662 |
|
|
2018
Q4 | – | Sell |
-100,181
| Closed | -$379K | – | 697 |
|
|
2018
Q3 | $379K | Buy |
100,181
+16,000
| +19% | +$50.1K | 0.04% | 446 |
|
|
2018
Q2 | $263K | Sell |
84,181
-38,819
| -32% | -$118K | 0.02% | 522 |
|
|
2018
Q1 | $294K | Buy |
+123,000
| New | +$409K | 0.03% | 476 |
|
|
2017
Q3 | – | Sell |
-68,970
| Closed | -$190K | – | 622 |
|
|
2017
Q2 | $190K | Sell |
68,970
-66,902
| -49% | -$140K | 0.04% | 572 |
|
|
2017
Q1 | $265K | Buy |
+135,872
| New | +$173K | 0.05% | 476 |
|
|
2016
Q1 | – | Sell |
-39,695
| Closed | -$97K | – | 622 |
|
|
2015
Q4 | $97K | Sell |
39,695
-23,972
| -38% | -$68.7K | 0.04% | 507 |
|
|
2015
Q3 | $191K | Buy |
+63,667
| New | +$275K | 0.09% | 333 |
|
Other funds holding CPRX
Boothbay Fund Management's CPRX Position: Q3 2026 in Review
Boothbay Fund Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 9,701 shares — an estimated $305K sold.
Boothbay Fund Management first reported a position in CPRX in Q3 2015 and held it in 18 quarters. The position peaked at $2.11M in Q3 2024. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- Boothbay Fund Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Boothbay Fund Management sold 9,701 Catalyst Pharmaceutical shares in Q3 2026, an estimated $305K.
- Boothbay Fund Management first reported a position in Catalyst Pharmaceutical in Q3 2015 and held it in 18 quarters.
- Boothbay Fund Management's Catalyst Pharmaceutical position peaked at $2.11M in Q3 2024.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.